Old drug - New indication. Rifampicin in psoriasis

Journal of Dermatological Treatment

Volumn 17, Issue 1, 2006, Pages 18-23

  Tsankov, Nikolai ^a   Grozdev, Ivan ^a   Kazandjieva, Jana ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Eruptive psoriasis; PASI; Rifampicin

Indexed keywords

ANTIINFECTIVE AGENT; EMOLLIENT AGENT; IMMUNOSUPPRESSIVE AGENT; RIFAMPICIN;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL ACTIVITY; ARTICLE; CHI SQUARE TEST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; SCHOOL CHILD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RIFAMPIN; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 32644489793     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630500375643     Document Type: Article

References (27)

1. Maggu N, Pasqualucci CR, Ballota R, Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy. 1966;11:285-92.
2. Tsankov N, Kamarashev J. Rifampin in dermatology. Int J Dermatol. 1993;32:401-6.
3. Tsankov N, Angelova I. Rifampin in dermatology. Clin Dermatol. 2003;21:50-5.
4. Flandin F. L'action de la penicilline dans le psoriasis. Bull Soc Fr Dermatol Syphiligr. 1959;66:494-502.
5. Rosenberg EW, Belew W. Microbial factors of psoriasis. Arch Dermatol. 1982;118:143-4.
6. Rosenberg EW, Noah PW, Zanolli MD, Skinner RB Jr, Bond MJ, Crutcher N. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. J Am Acad Dermatol. 1986;14:761-4.
7. Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol. 1992;26:458-61.
8. Tsankov N, Krasteva M. Rifampin in severe forms of psoriasis. J Dermatol Treat. 1992;3:69-71.
9. Tsankov N. Drug therapy in patients with psoriasis vulgaris - risks and perspectives [Thesis]. Sofia, 1996.
10. Kazandjieva J, Kamarashev J, Hinkov G. Alleviation of psoriasis by rifampicin in the treatment of pulmonary tuberculosis. J Dermatol Treat. 1993;4:163-5 [letter].
11. Kazandjieva J, Kamarashev J, Hinkov G, Tsankov N. Rifampicin und Psoriasis. Aktuelle Derm. 1997;23:78-81.
12. Tsankov N, Kazandjieva J, Grozdev I. Treatment of psoriasis with rifampicin. Is rifampicin an immunosuppressive antibiotic? European Congress on Psoriasis, Paris, 21-24 October 2004 [poster presentation] (p. 084).
13. Tsankov N, Grozdev I. Unusual antibiotic use in dermatology - penicillins, tetracyclines, rifamycins. EADV Annual Congress, London, 12-16 October 2005 [oral communication] (CD-ROM).
14. Nörholm-Pedersen A. Infections and psoriasis. Acta Derm Venereol. 1952;32:159-67.
15. Farber EM, Nall L. Epidemiology, natural history and genetics. In: Roenigk HH, Maibach HI, editors. Psoriasis. 3rd ed. New York, Basel, Hong Kong: Marcel Dekker; 1998. p. 107-57.
16. Farber EM, Nall L. Guttate psoriasis. Cutis. 1993;51:157-64.
17. Yamamoto T, Katayama I, Nishioka K. Clinical analysis of staphylococcal superantigen hyper-reactive patients with psoriasis vulgaris. Eur J Dermatol. 1998;8:325-9.
18. Vladimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens. Immunol Today. 1995;16:145-9.
19. Blok S, Vissers WHPM, van Duijnhoven M, van de Kerkhof PCM. Aggravation of psoriasis by infections: a constitutional trait or a variable expression? Eur J Dermatol. 2004;14:259-61.
20. Owen CM, Chalmers RJG, O'Sullivan T, Griffiths CEM. A systematic review of antistreptococcal interventions for guttate and chronic psoriasis. Br J Dermatol. 2001;145:886-90.
21. Farr BF. Rifamycins. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1995. p. 317-29.
22. Paunescu E. In vivo and in vitro suppression of humoral and cellular response by rifampicin. Nature. 1970;229:1188-9.
23. Nilsson BS. Rifampicin: an immunosuppressant? Lancet. 1971;ii:374.
24. Dajani BM, Canadi MS, Thompson JS, Kasisk JE. Rifampicin: an immunosuppressant? Lancet. 1972;ii:1904.
25. Gupta S, Grieco MH, Siegel I. Suppression of T-lymphocyte rosettes by rifampicin. Studies in normals and patients with tuberculosis. Ann Intern Med. 1975;82:484-8.
26. Mlambo G, Sigola LB. Rifampicin and dexamethasone have similar effects on macrophage phagicytosis of zymosan, but differ in their effects on nitrite and TNF-alpha production. Int Immunopharmacol. 2003;3:513-22.
27. Ziglam HM, Daniels I, Finch RG. Immunomodulating activity of rifampicin. J Chemother. 2004;16:357-61.